ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles

被引:8
作者
Reznickova, Eva [1 ,2 ]
Tenora, Lukas [3 ]
Pospisilova, Pavlina [1 ,2 ]
Galeta, Juraj [3 ,6 ]
Jorda, Radek [1 ,2 ]
Berka, Karel [4 ]
Majer, Pavel [5 ]
Potacek, Milan [3 ]
Krystof, Vladimir [1 ,2 ]
机构
[1] Palacky Univ, Ctr Region Hana Biotechnol & Agr Res, Lab Growth Regulators, Slechtitelu 27, Olomouc 78371, Czech Republic
[2] Inst Expt Bot AS CR, Slechtitelu 27, Olomouc 78371, Czech Republic
[3] Masaryk Univ, Fac Sci, Dept Chem, Kotlarska 2, CS-61137 Brno, Czech Republic
[4] Palacky Univ, Fac Sci, Reg Ctr Adv Technol & Mat, Dept Phys Chem, 17 listopadu 12, Olomouc 77146, Czech Republic
[5] Acad Sci Czech Republ, Inst Organ Chem & Biochem, Flemingovo Nam 2, CR-16610 Prague, Czech Republic
[6] Columbia Univ, Dept Chem, New York, NY 10027 USA
关键词
Transforming growth factor beta receptor I; Protein kinase; Inhibitor; Substituted pyrrolo[1,2-b]pyrazoles; I-RECEPTOR KINASE; BETA SIGNALING PATHWAY; SMALL-MOLECULE INHIBITOR; TGF-BETA; DOMAIN INHIBITORS; GROWTH; FIBROSIS; CANCER; POTENT; SERIES;
D O I
10.1016/j.ejmech.2017.01.018
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 2,3,4-substituted 5,5-dimethy1-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles (DPPs) was synthesized and evaluated for their ALK5 inhibition activity. The most potent compounds displayed submicromolar IC50 values for ALK5. Preliminary profiling of one of the most active compounds in a panel of 50 protein kinases revealed its selectivity for ALK5. In cells, the compounds caused dose-dependent dephosphorylation of SMAD2, a well-established substrate of ALK5. In addition, the compounds blocked translocation of SMAD2/3 to nuclei of cells stimulated with TGF beta Tap and the protein remained predominantly in cytoplasm, further confirming their molecular target. Therefore, novel DPP derivatives proved to be active as ALK5 inhibitors. (C) 2017 Elsevier Masson SAS.
引用
收藏
页码:632 / 642
页数:11
相关论文
共 28 条
  • [1] Targeting the TGFβ signalling pathway in disease
    Akhurst, Rosemary J.
    Hata, Akiko
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (10) : 790 - 811
  • [2] The selectivity of protein kinase inhibitors: a further update
    Bain, Jenny
    Plater, Lorna
    Elliott, Matt
    Shpiro, Natalia
    Hastie, C. James
    Mclauchlan, Hilary
    Klevernic, Iva
    Arthur, J. Simon C.
    Alessi, Dario R.
    Cohen, Philip
    [J]. BIOCHEMICAL JOURNAL, 2007, 408 : 297 - 315
  • [3] Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice
    Bueno, Lorea
    de Alwis, Dinesh P.
    Pitou, Celine
    Yingling, Jonathan
    Lahn, Michael
    Glatt, Sophie
    Troconiz, Inaki F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 142 - 150
  • [4] Inhibition of TGF-β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis
    de Gouville, AC
    Boullay, V
    Krysa, G
    Pilot, J
    Brusq, JM
    Loriolle, F
    Gauthier, JM
    Papworth, SA
    Laroze, A
    Gellibert, F
    Huet, S
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2005, 145 (02) : 166 - 177
  • [5] TGF-β signaling in tumor suppression and cancer progression
    Derynck, R
    Akhurst, RJ
    Balmain, A
    [J]. NATURE GENETICS, 2001, 29 (02) : 117 - 129
  • [6] X-ray structure of glial cell-derived neurotrophic factor at 1.9 angstrom resolution and implications for receptor binding
    Eigenbrot, C
    Gerber, N
    [J]. NATURE STRUCTURAL BIOLOGY, 1997, 4 (06) : 435 - 438
  • [7] Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo
    Ge, Rongrong
    Rajeev, Vaishali
    Ray, Partha
    Lattime, Edmund
    Rittling, Susan
    Medicherla, Satya
    Protter, Andy
    Murphy, Alison
    Chakravarty, Jit
    Dugar, Sundeep
    Schreiner, George
    Barnard, Nicola
    Reiss, Michael
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4315 - 4330
  • [8] Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors
    Gellibert, F.
    Fouchet, M. -H.
    Nguyen, V. -L.
    Wang, R.
    Krysa, G.
    de Gouville, A. -C.
    Huet, S.
    Dodic, N.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (08) : 2277 - 2281
  • [9] Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis
    Grygielko, ET
    Martin, WM
    Tweed, C
    Thornton, P
    Harling, J
    Brooks, DP
    Laping, NJ
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03) : 943 - 951
  • [10] A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors
    Gucky, Tomas
    Jorda, Radek
    Zatloukal, Marek
    Bazgier, Vaclav
    Berka, Karel
    Reznickova, Eva
    Beres, Tibor
    Strnad, Miroslav
    Krystof, Vladimir
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (15) : 6234 - 6247